Inclusion Criteria:  Male or female subjects greater than or equal to 18 years old. Histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumor with KRAS mutation identified. Expected survival time ≥12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Must have at least one measureable lesion per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Have documented disease progression or intolerance after first-line treatment.  Exclusion Criteria:  Gastrointestinal (GI) tract disease causing the inability to take oral medication. Previous accept with KRAS G12C inhibitor. Uncontrollable general infection. Serious cardiovascular disease. Left ventricular ejection fraction (LVEF) <50 %. Known history of hypersensitivity to any of the excipients of GH35 tablets Pregnant or nursing (lactating) women.